BOSTON SCIENTIFIC CORPORATION (BSX) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $8.36B (period ending 2007-12-31) to $20.07B (period ending 2025-12-31) — a 5.0% annual pace across 18 year(s) of filed history.
- Not enough tagged Net income alongside Revenue to trace a margin.
- Across 55 tracked quarters, the strongest was $5.44B (quarter ending 2026-06-30) and the weakest was $1.71B (quarter ending 2013-03-31).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $20.07B | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Gross profit | $13.85B | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Operating income | $3.61B | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Diluted EPS | $1.94 | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Total assets | $43.67B | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Cash & equivalents | $1.97B | 2025-12-31 | 10-K | 0000885725-26-000010 |
| Operating cash flow | $4.53B | 2025-12-31 | 10-K | 0000885725-26-000010 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $5.44B | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Gross profit | $3.85B | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Operating income | $1.18B | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Net income | $190.0M | 2010-09-30 | 10-Q | 0000950123-10-101570 |
| Diluted EPS | $0.61 | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Total assets | $45.22B | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Cash & equivalents | $539.0M | 2026-06-30 | 10-Q | 0000885725-26-000053 |
| Operating cash flow | $348.0M | 2026-03-31 | 10-Q | 0000885725-26-000033 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Boston Scientific Corporation (BSX) operates in the medical devices industry, with a substantial scale evident from its $20.07 billion annual revenue in 2025. Over an 18-year period, the company has demonstrated steady growth at a compound annual rate of 5.0%, as per the pre-computed trend facts. This consistent expansion underscores the company’s established market presence and product portfolio appeal.
The multi-year revenue trajectory reveals a gradual upward slope, with notable increases observed from 2019 to 2025, where revenues quadrupled from $4.8 billion to $20.07 billion. This growth is particularly significant when considering the company’s historical revenue fluctuations, suggesting a successful strategic shift or market penetration during this period.
In terms of profitability, while detailed net income trends cannot be accurately assessed due to insufficient data, the quarterly figures indicate that Boston Scientific has managed to maintain robust operating cash flows, reaching $4.53 billion annually in 2025 and $348 million in Q1 2026. Investors should monitor future filings for further insights into net income trends and margin developments, as these metrics will be crucial in evaluating the company’s operational efficiency and overall financial health.
Source: SEC EDGAR company facts for CIK 0000885725 · filings index